Manu V. Chakravarthy

5.7k citations

52 papers · 4.1k indexed · h-index 27

Physiology top 1%
- Diet and metabolism studies 7
- Adipose Tissue and Metabolism 6
- Telomeres, Telomerase, and Senescence 5
Biochemistry top 1%
Aging top 5%
Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management 7
Epidemiology top 2%
- Liver Disease Diagnosis and Treatment 15
Molecular Biology
- Muscle Physiology and Disorders 9
- Peroxisome Proliferator-Activated Receptors 6
Pharmacology
- Pharmacology and Obesity Treatment 6

Co-authors: Frank W. Booth Clay F. Semenkovich Espen E. Spangenburg John Turk Trey Coleman Jochen G. Schneider Michael J. Joyner Li Yin
Cited by: Physiology Biochemistry Aging
Journals: Cell (1 paper)Journal of Biological Chemistry (3 papers)Journal of Clinical Investigation (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

Manu V. Chakravarthy

50 papers receiving 4.0k citations

Peers

Countries citing papers authored by Manu V. Chakravarthy

Since Specialization

Citations

This map shows the geographic impact of Manu V. Chakravarthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manu V. Chakravarthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manu V. Chakravarthy more than expected).

Fields of papers citing papers by Manu V. Chakravarthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manu V. Chakravarthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manu V. Chakravarthy. The network helps show where Manu V. Chakravarthy may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Manu V. Chakravarthy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Manu V. Chakravarthy Line = papers co-authored together Manu V. Chakravarthy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial Diabetes Obesity and Metabolism ·Manu V. Chakravarthy,Michael Elliott,Luis F. Acosta,Gabriele E. Sonnenberg,Damian Bialonczyk,Jingtao Wu,FEDERICO A. ARGÜELLES-TELLO,Raymundo Garcia Cota,José Gerardo González‐González,Stig K. Hansen,Juan P. Frías	2025	1
2	Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy Cell Reports Medicine ·Rubén Rodríguez,Anne C. Hergarden,Shyam Krishnan,Marikris Morales,D. K. C. Lam,Ted Tracy,Teresa Tang,A. R. Patton,Craig R. Lee,Asmita Pant,Daniel A. Erlanson,Johan Enquist,Derek B.J. Bone,Ray Fucini,Damian Bialonczyk,Stig K. Hansen,Jian Luo,Manu V. Chakravarthy	2025	2
3	An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I Diabetes Obesity and Metabolism ·Snezana Milanovic,Robert Lew,Kuangnan Xiong,Emily Casavant,Gerald R. Galluppi,Yu‐Luan Chen,Yongquan Lai,Manu V. Chakravarthy,Clay Dehn,Kenneth S. Koblan,Seth C. Hopkins	2025	0
4	Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease The American Journal of Gastroenterology ·Stephen A. Harrison,Seth J. Baum,Nadege Gunn,Ziad Younes,Anita Kohli,Rashmee Patil,Margaret James Koziel,Harinder Chera,Jeff Zhao,Manu V. Chakravarthy	2021	18
5	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis Frontiers in Endocrinology ·Andrea Dennis,Matt Kelly,Carolina Fernandes,Sofia Mouchti,Jonathan Fallowfield,Gideon M. Hirschfield,Michael Pavlides,Stephen A. Harrison,Manu V. Chakravarthy,Rajarshi Banerjee,Arun J. Sanyal	2021	67
6	The metabolic basis of nonalcoholic steatohepatitis Endocrinology Diabetes & Metabolism ·Manu V. Chakravarthy,Brent A. Neuschwander‐Tetri	2020	68
7	Endogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids iScience ·Michael J. Hamill,Raffi Afeyan,Manu V. Chakravarthy,Tony Tramontin	2020	14
8	Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects Clinical Drug Investigation ·Rebecca E. Wrishko,Jacqueline B. McCrea,Ka Lai Yee,Wen Liu,Deborah Panebianco,Eric Mangin,Manu V. Chakravarthy,Maria P. Martinez Cantarin,Walter K. Kraft	2019	15
9	Decreased complexity of glucose dynamics preceding the onset of diabetes in mice and rats PLoS ONE ·Xiaohua Douglas Zhang,David Pechter,Liming Yang,Xiaoli Ping,Zuliang Yao,Rumin Zhang,Xiaolan Shen,Nina Xiaoyan Li,J.H. Connick,Andrea R. Nawrocki,Manu V. Chakravarthy,Cai Li	2017	15
10	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation Cell Metabolism ·Chai-Wan Kim,Carol Addy,Jun Kusunoki,Norma N. Anderson,Stanisław Deja,Xiaorong Fu,Shawn C. Burgess,Li Cai,Marcie Ruddy,Manu V. Chakravarthy,Steve Previs,Stuart Milstein,Kevin Fitzgerald,David E. Kelley,Jay D. Horton	2017	314
11	Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes BMC Obesity ·Sudha S. Shankar,Lori Mixson,Manu V. Chakravarthy,Robin Chisholm,Anthony J. Acton,RoseMarie Jones,Samer G. Mattar,Deborah L. Miller,Lea Petry,Chan Beals,S. Aubrey Stoch,David E. Kelley,Robert V. Considine	2017	15
12	Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium Obesity Reviews ·Charmaine S. Tam,Hans‐Rudolf Berthoud,Marco Bueter,Manu V. Chakravarthy,Allan Geliebter,A. Hajnal,Jens J. Holst,Lee M. Kaplan,Walter J. Pories,Helen E. Raybould,Randy J. Seeley,April D. Strader,Éric Ravussin	2011	37
13	Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver Cell ·Manu V. Chakravarthy,Irfan J. Lodhi,Li Yin,Raghu R.V. Malapaka,H. Eric Xu,John Turk,Clay F. Semenkovich	2009	420
14	Inactivation of hypothalamic FAS protects mice from diet-induced obesity and inflammation Journal of Lipid Research ·Manu V. Chakravarthy,Yimin Zhu,Yin Li,Trey Coleman,Kirk L. Pappan,Connie A. Marshall,Michael L. McDaniel,Clay F. Semenkovich	2008	39
15	Respiratory Uncoupling in Skeletal Muscle Delays Death and Diminishes Age-Related Disease Cell Metabolism ·Allison C. Gates,Carlos Bernal‐Mizrachi,Sharon L. Chinault,Feng Chu,Jochen G. Schneider,Trey Coleman,James P. Malone,R. Reid Townsend,Manu V. Chakravarthy,Clay F. Semenkovich	2007	94
16	“New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis Cell Metabolism ·Manu V. Chakravarthy,Zhijun Pan,Yimin Zhu,Karen Tordjman,Jochen G. Schneider,Trey Coleman,John Turk,Clay F. Semenkovich	2005	436
17	p27Kip1: A Key Regulator of Skeletal Muscle Satellite Cell Proliferation Clinical Orthopaedics and Related Research ·Espen E. Spangenburg,Manu V. Chakravarthy,Frank W. Booth	2002	17
18	Exercise and gene expression: physiological regulation of the human genome through physical activity The Journal of Physiology ·Frank W. Booth,Manu V. Chakravarthy,Espen E. Spangenburg	2002	180
19	An Obligation for Primary Care Physicians to Prescribe Physical Activity to Sedentary Patients to Reduce the Risk of Chronic Health Conditions Mayo Clinic Proceedings ·Manu V. Chakravarthy,Michael J. Joyner,Frank W. Booth	2002	133
20	Long-term insulin-like growth factor-I expression in skeletal muscles attenuates the enhanced in vitro proliferation ability of the resident satellite cells in transgenic mice Mechanisms of Ageing and Development ·Manu V. Chakravarthy,Marta L. Fiorotto,Robert J. Schwartz,Frank W. Booth	2001	19

About Manu V. Chakravarthy

Manu V. Chakravarthy is a scholar working on Aging, Physiology and Endocrinology, Diabetes and Metabolism, having authored 52 papers that have together received 4.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (15 papers), Muscle Physiology and Disorders (9 papers), Diet and metabolism studies (7 papers), Diabetes Treatment and Management (7 papers), Pharmacology and Obesity Treatment (6 papers), Peroxisome Proliferator-Activated Receptors (6 papers), Adipose Tissue and Metabolism (6 papers) and Telomeres, Telomerase, and Senescence (5 papers). The work is most often cited by research in Physiology (1.6k citations), Biochemistry (368 citations) and Aging (81 citations). Manu V. Chakravarthy has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Frank W. Booth, Clay F. Semenkovich, Espen E. Spangenburg, John Turk, Trey Coleman, Jochen G. Schneider, Michael J. Joyner, Frank W. Booth, Li Yin and Yimin Zhu. Their work appears in journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact